Nuzenio

Selinexor Misses Primary

Selinexor Misses Primary news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Weekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTMoleculin Biotech updates Annamycin data, prices stock offering at $0.75 - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:43:05 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTSelinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 20:06:29 GMTSelinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLiveOncLive · Fri, 31 Jul 2026 17:22:55 GMTSelinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 14:37:53 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 14:00:00 GMTKaryopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingViewTradingView · Fri, 31 Jul 2026 12:33:01 GMT

Timeline

Mon, 03 Aug 2026 11:33:04 GMTWeekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingView
Sat, 01 Aug 2026 06:43:05 GMTMoleculin Biotech updates Annamycin data, prices stock offering at $0.75 - The Clinical Trial Vanguard
Sat, 01 Aug 2026 06:33:05 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Fri, 31 Jul 2026 20:06:29 GMTSelinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology
Fri, 31 Jul 2026 17:22:55 GMTSelinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive
Fri, 31 Jul 2026 14:37:53 GMTSelinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Selinexor Misses Primary.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.